ATG-fresenius treatment and low-dose tacrolimus: Results of a randomized controlled trial in liver transplantation

American Journal of Transplantation

Volumn 10, Issue 10, 2010, Pages 2296-2304

  Benitez C E ^a   Puig Pey, I ^a   Lopez M ^a   Martinez Llordella M ^a   Lozano, J J ^b   Bohne, F ^a   Londono M C ^a   Garcia Valdecasas J C ^c   Bruguera, M ^a   Navasa, M ^a   Rimola, A ^a   Sanchez Fueyo A ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

T cell depletion; Tacrolimus monotherapy; tacrolimus weaning; tolerance induction; transplantation

Indexed keywords

DIPHENHYDRAMINE; METHYLPREDNISOLONE; PARACETAMOL; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTERY THROMBOSIS; ARTICLE; BACTERIAL INFECTION; BILE DUCT OBSTRUCTION; BILOMA; CASE REPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GENE EXPRESSION; HEPATIC ARTERY THROMBOSIS; HUMAN; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY T LYMPHOCYTE; MONOTHERAPY; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 77957191625     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03164.x     Document Type: Article

References (26)

1. Ojo A, Held P, Port F et al. Chronic renal failure after transplantation of a non renal organ. N Engl J Med 2003 349: 931 940. (Pubitemid 37064766)
2. Schlitt HJ, Barkmann A, Böker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients. Lancet 2001 357: 587 591.
3. Stegall MD, Everson GT, Schroter G et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997 25: 173 177. (Pubitemid 27015006)
4. Fishman J. Infection in solid-organ transplantation. N Engl J Med 2007 357: 2601 2614.
5. Pruthi J, Medkiff K, Erason K et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001 7: 811 815. (Pubitemid 32851304)
6. Lerut J, Sánchez Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006 6: 1774 1780. (Pubitemid 44024949)
7. Martínez-Llordella M, Lozano J, Puig-Pey I et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008 118: 2845 2857.
8. Calne R. WOFIE hypothesis: Some thoughts on an approach toward allograft tolerance. Transplant Proc 1996 28: 1152. (Pubitemid 26195148)
9. Starzl TE, Zinkernagel R. Transplantation tolerance from a historical perpective. Nat Rev Immunol 2001 1: 233 239.
10. Calne R, Friend P, Moffatt S et al. Prope Tolerance, perioperative Campath 1H, and low dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998 351: 1701 1702. (Pubitemid 28254534)
11. Swanson S, Hale D, Mannon R et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002 360: 1662 1664. (Pubitemid 35379741)
12. Shapiro R, Jordan M, Basu A et al. Kidney transplantation under a tolerogenic regime of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003 238: 520 527. (Pubitemid 38176389)
13. Knechtle S, Pirsch J, Fechner J et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 3: 722 730. (Pubitemid 36745245)
14. Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppresion for organ transplantation. Lancet 2003 361: 1502 1510.
15. Marcos A, Eghtesad B, Fung J et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus. Transplantation 2004 78: 966 971. (Pubitemid 39391856)
16. De Ruvo N, Cucchetti A, Lauro A et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005 80: 8 12. (Pubitemid 40980888)
17. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th Ed. New York: Springer, 2002: 1 495.
18. Neuberger NM, Mamelok RD, Neuhaus P et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The 'ReSpECT' study. Am J Transplant 2009 9: 327 337.
19. Donkier V, Cracium L, Lucidi V et al. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: Potential role of IFN-γ-secreting CD8+ T cells. Transplantation 2009 87: S91 S95.
20. Eason JD, Cohen AJ, Satheesh N, Alcantera T, Loss GE. Tolerance: Is it worth the risk Transplantation 2005 79: 1157 1159.
21. Lopez M, Clarkson M, Albin M, Sayegh M, Najafian N. A novel mechanism of action for anti-thymocyte globuline: Induction of CD4+CD25+FoxP3+ regulatory T cells. J Am Soc Nephrol 2006 17: 2844 2853.
22. Bestard O, Cruzado J, Mestre M et al. Achieving donor-specific hyporesponsiveness is associated with FoxP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007 179: 4901 4909.
23. Pons JA, Revilla-Nuin B, Baroja-Mazo A et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008 86: 1370 1378.
24. Demirkiran A, Sewgobind VD, Van Der Weijde J et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation 2009 87: 1062 1068.
25. Page AJ, Ford ML, Kirk AD. Memory T cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant 2009 14: 643 649.
26. Pearl J, Parris J, Hale D et al. Immunocompetent T cells with a memory-like phenotype are the dominant cell type following antibody-mediated T cell depletion. Am J Transplant 2005 5: 465 474. (Pubitemid 40313337)